Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis

Results of a Randomized Trial

Keith Lindor, Kris V. Kowdley, E. Jenny Heathcote, M. Edwyn Harrison, Roberta Jorgensen, Paul Angulo, James F. Lymp, Lawrence Burgart, Patrick Colin

Research output: Contribution to journalArticle

528 Citations (Scopus)

Abstract

No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy-proven NASH to receive between 13 and 15 mg/kg/d of UDCA or placebo for 2 years. End points included changes in liver test results and liver histology at 2 years of therapy. The treatment groups were comparable at entry with regard to age, gender, risk factors for NASH, serum liver biochemistries, and baseline liver histology. A total of 126 patients completed 2 years of therapy. Pre- and posttreatment liver biopsies were available in 107 patients for review at the end of the study. UDCA was well tolerated and body weight was stable during the study duration. Serum liver biochemistries were stable or improved in both the UDCA and placebo-treated groups. Changes in the degree of steatosis, necroinflammation, or fibrosis that occurred with therapy were not significantly different between the UDCA and placebo groups. In conclusion, 2 years of therapy with UDCA at a dose of 13 to 15 mg/kg/d, although safe and well tolerated, is not better than placebo for patients with NASH.

Original languageEnglish (US)
Pages (from-to)770-778
Number of pages9
JournalHepatology
Volume39
Issue number3
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Liver
Placebos
Biochemistry
Therapeutics
Histology
Biopsy
Non-alcoholic Fatty Liver Disease
Serum
Fibrosis
Body Weight

ASJC Scopus subject areas

  • Hepatology

Cite this

Lindor, K., Kowdley, K. V., Heathcote, E. J., Harrison, M. E., Jorgensen, R., Angulo, P., ... Colin, P. (2004). Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis: Results of a Randomized Trial. Hepatology, 39(3), 770-778. https://doi.org/10.1002/hep.20092

Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis : Results of a Randomized Trial. / Lindor, Keith; Kowdley, Kris V.; Heathcote, E. Jenny; Harrison, M. Edwyn; Jorgensen, Roberta; Angulo, Paul; Lymp, James F.; Burgart, Lawrence; Colin, Patrick.

In: Hepatology, Vol. 39, No. 3, 03.2004, p. 770-778.

Research output: Contribution to journalArticle

Lindor, K, Kowdley, KV, Heathcote, EJ, Harrison, ME, Jorgensen, R, Angulo, P, Lymp, JF, Burgart, L & Colin, P 2004, 'Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis: Results of a Randomized Trial', Hepatology, vol. 39, no. 3, pp. 770-778. https://doi.org/10.1002/hep.20092
Lindor, Keith ; Kowdley, Kris V. ; Heathcote, E. Jenny ; Harrison, M. Edwyn ; Jorgensen, Roberta ; Angulo, Paul ; Lymp, James F. ; Burgart, Lawrence ; Colin, Patrick. / Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis : Results of a Randomized Trial. In: Hepatology. 2004 ; Vol. 39, No. 3. pp. 770-778.
@article{e867a9cf7c6a4c74a2c56262f73483e2,
title = "Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis: Results of a Randomized Trial",
abstract = "No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy-proven NASH to receive between 13 and 15 mg/kg/d of UDCA or placebo for 2 years. End points included changes in liver test results and liver histology at 2 years of therapy. The treatment groups were comparable at entry with regard to age, gender, risk factors for NASH, serum liver biochemistries, and baseline liver histology. A total of 126 patients completed 2 years of therapy. Pre- and posttreatment liver biopsies were available in 107 patients for review at the end of the study. UDCA was well tolerated and body weight was stable during the study duration. Serum liver biochemistries were stable or improved in both the UDCA and placebo-treated groups. Changes in the degree of steatosis, necroinflammation, or fibrosis that occurred with therapy were not significantly different between the UDCA and placebo groups. In conclusion, 2 years of therapy with UDCA at a dose of 13 to 15 mg/kg/d, although safe and well tolerated, is not better than placebo for patients with NASH.",
author = "Keith Lindor and Kowdley, {Kris V.} and Heathcote, {E. Jenny} and Harrison, {M. Edwyn} and Roberta Jorgensen and Paul Angulo and Lymp, {James F.} and Lawrence Burgart and Patrick Colin",
year = "2004",
month = "3",
doi = "10.1002/hep.20092",
language = "English (US)",
volume = "39",
pages = "770--778",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis

T2 - Results of a Randomized Trial

AU - Lindor, Keith

AU - Kowdley, Kris V.

AU - Heathcote, E. Jenny

AU - Harrison, M. Edwyn

AU - Jorgensen, Roberta

AU - Angulo, Paul

AU - Lymp, James F.

AU - Burgart, Lawrence

AU - Colin, Patrick

PY - 2004/3

Y1 - 2004/3

N2 - No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy-proven NASH to receive between 13 and 15 mg/kg/d of UDCA or placebo for 2 years. End points included changes in liver test results and liver histology at 2 years of therapy. The treatment groups were comparable at entry with regard to age, gender, risk factors for NASH, serum liver biochemistries, and baseline liver histology. A total of 126 patients completed 2 years of therapy. Pre- and posttreatment liver biopsies were available in 107 patients for review at the end of the study. UDCA was well tolerated and body weight was stable during the study duration. Serum liver biochemistries were stable or improved in both the UDCA and placebo-treated groups. Changes in the degree of steatosis, necroinflammation, or fibrosis that occurred with therapy were not significantly different between the UDCA and placebo groups. In conclusion, 2 years of therapy with UDCA at a dose of 13 to 15 mg/kg/d, although safe and well tolerated, is not better than placebo for patients with NASH.

AB - No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy-proven NASH to receive between 13 and 15 mg/kg/d of UDCA or placebo for 2 years. End points included changes in liver test results and liver histology at 2 years of therapy. The treatment groups were comparable at entry with regard to age, gender, risk factors for NASH, serum liver biochemistries, and baseline liver histology. A total of 126 patients completed 2 years of therapy. Pre- and posttreatment liver biopsies were available in 107 patients for review at the end of the study. UDCA was well tolerated and body weight was stable during the study duration. Serum liver biochemistries were stable or improved in both the UDCA and placebo-treated groups. Changes in the degree of steatosis, necroinflammation, or fibrosis that occurred with therapy were not significantly different between the UDCA and placebo groups. In conclusion, 2 years of therapy with UDCA at a dose of 13 to 15 mg/kg/d, although safe and well tolerated, is not better than placebo for patients with NASH.

UR - http://www.scopus.com/inward/record.url?scp=1542515099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542515099&partnerID=8YFLogxK

U2 - 10.1002/hep.20092

DO - 10.1002/hep.20092

M3 - Article

VL - 39

SP - 770

EP - 778

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -